Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Head and neck cancer Stories

2012-04-02 20:47:18

Results could lead to personalized treatment strategies for patients with this type of cancer Squamous cell carcinoma of the head and neck–which typically arises from thin, flat cells that line moist surfaces inside the mouth, nose and throat–is the sixth most common type of cancer worldwide, and it has a relatively low five-year survival rate and a high recurrence rate. Recently, the disease has become even more prevalent among adults 40 years of age or younger. These...

2012-04-02 15:29:57

Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute. New research from scientists at Fox Chase Cancer Center in...

2012-04-02 15:28:44

Fox Chase scientists suggest that the findings could also serve as a new target for treatment Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1. The researchers found that patients whose tumors had higher levels of the protein...

2012-04-02 10:24:52

SYRACUSE, N.Y., April 2, 2012 /PRNewswire/ -- Aspen Dental, one of the largest and fastest-growing networks of dental care providers in the U.S., is reminding patients about the importance of oral cancer screening and early detection in recognition of Oral Cancer Awareness Month (April). According to the Oral Cancer Foundation, close to 37,000 Americans will be diagnosed with oral or pharyngeal cancer this year, which is responsible for approximately 8,000 deaths annually. Common...

2012-04-02 02:27:40

CALGARY, April 2, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018). "This is an important milestone for this study," said Dr. Brad Thompson, President and CEO of Oncolytics. "A data analysis that will...

2012-03-29 13:42:47

Research led by Lauren Cole, a public health graduate student, and Dr. Edward Peters, Associate Professor of Public Health and Director of the Epidemiology Program at LSU Health Sciences Center New Orleans, reports that the incidence of head and neck cancer has risen at sites associated with Human Papilloma Virus (HPV) infection, with the greatest increase among middle-aged white men. At the same time, younger, Non-Hispanic blacks experienced a substantial decrease in these cancers. They also...

2012-03-29 02:25:43

CALGARY, March 29, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) announced today that abstracts of preclinical research on reovirus (REOLYSIN(®)) are available on the American Association for Cancer Research (AACR) website at www.aacr.org. The research is scheduled to be presented at the 2012 AACR Annual Meeting in Chicago, IL, which takes place from March 31 to April 4, 2012. "We are delighted to see that the research community has been...

2012-03-22 02:24:46

SAN DIEGO, March 22, 2012 /PRNewswire/ -- OncoSec Medical Incorporated. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been selected to present data from its Phase III and IV head and neck cancer studies at two upcoming conferences. Data from the Phase IV study carried out in Europe has been selected for a poster session and special oral presentation at the 5th...

2012-03-15 06:00:00

CALGARY, March 15, 2012 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2011. "In the last year we made substantial progress as we announced positive clinical trial results and started clinical trials in additional cancer indications while maintaining the strength of our balance sheet," said Dr. Brad Thompson, President and CEO of Oncolytics....

2012-03-13 05:01:00

SAN DIEGO, March 13, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Punit Dhillon, President and CEO, has written an article for Today's Medical Developments with the focus of addressing the medical industry's challenge in finding a safe and effective method for delivering potentially useful agents to treat solid tumor cancers....